作为 OX1R 选择性 PET 配体候选化合物的苏沃先的杂芳基衍生物:铜介导的硼氧烷 18F 氟化、体外和初步体内评估。

IF 4.3 3区 材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC
Kim-Viktoria Bolik, Jan Hellmann, Simone Maschauer, Eduard Neu, Jürgen Einsiedel, Patrick Riss, Nora Vogg, Jörg König, Martin F Fromm, Harald Hübner, Peter Gmeiner, Olaf Prante
{"title":"作为 OX1R 选择性 PET 配体候选化合物的苏沃先的杂芳基衍生物:铜介导的硼氧烷 18F 氟化、体外和初步体内评估。","authors":"Kim-Viktoria Bolik, Jan Hellmann, Simone Maschauer, Eduard Neu, Jürgen Einsiedel, Patrick Riss, Nora Vogg, Jörg König, Martin F Fromm, Harald Hübner, Peter Gmeiner, Olaf Prante","doi":"10.1186/s13550-024-01141-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The orexin receptor (OXR) plays a role in drug addiction and is aberrantly expressed in colorectal tumors. Subtype-selective OXR PET ligands suitable for in vivo use have not yet been reported. This work reports the development of <sup>18</sup>F-labeled OXR PET ligand candidates derived from the OXR antagonist suvorexant and the OX1R-selective antagonist JH112.</p><p><strong>Results: </strong>Computational analysis predicted that fluorine substitution (1e) and introduction of the fluorobenzothiazole scaffold (1f) would be suitable for maintaining high OX1R affinity. After multi-step synthesis of 1a-1f, in vitro OXR binding studies confirmed the molecular dynamics calculations and revealed single-digit nanomolar OX1R affinities for 1a-f, ranging from 0.69 to 2.5 nM. The benzothiazole 1f showed high OX1R affinity (K<sub>i</sub> = 0.69 nM), along with 77-fold subtype selectivity over OX2R. Cu-mediated <sup>18</sup>F-fluorination of boroxine precursors allowed for a shortened reaction time of 5 min to provide the non-selective OXR ligand [<sup>18</sup>F]1c and its selective OX1R congener [<sup>18</sup>F]1f in activity yields of 14% and 22%, respectively, within a total synthesis time of 52-76 min. [<sup>18</sup>F]1c and [<sup>18</sup>F]1f were stable in plasma and serum in vitro, with logD<sub>7.4</sub> of 2.28 ([<sup>18</sup>F]1c) and 2.37 ([<sup>18</sup>F]1f), and high plasma protein binding of 66% and 77%, respectively. Dynamic PET imaging in rats showed similar brain uptake of [<sup>18</sup>F]1c (0.17%ID/g) and [<sup>18</sup>F]1f (0.15%ID/g). However, preinjection of suvorexant did not significantly block [<sup>18</sup>F]1c or [<sup>18</sup>F]1f uptake in the rat brain. Pretreatment with cyclosporine A to study the role of P-glycoprotein (P-gp) in limiting brain accumulation moderately increased brain uptake of [<sup>18</sup>F]1c and [<sup>18</sup>F]1f. Accordingly, in vitro experiments demonstrated that the P-gp inhibitor zosuquidar only moderately inhibited polarized, basal to apical transport of 1c (p < 0.05) and had no effect on the transport of 1f, indicating that P-gp does not play a relevant role in brain accumulation of [<sup>18</sup>F]1c and [<sup>18</sup>F]1f in vivo.</p><p><strong>Conclusions: </strong>The in vitro and in vivo results of [<sup>18</sup>F]1c and [<sup>18</sup>F]1f provide a solid basis for further development of suitable OXR PET ligands for brain imaging.</p>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11374953/pdf/","citationCount":"0","resultStr":"{\"title\":\"Heteroaryl derivatives of suvorexant as OX1R selective PET ligand candidates: Cu-mediated <sup>18</sup>F-fluorination of boroxines, in vitro and initial in vivo evaluation.\",\"authors\":\"Kim-Viktoria Bolik, Jan Hellmann, Simone Maschauer, Eduard Neu, Jürgen Einsiedel, Patrick Riss, Nora Vogg, Jörg König, Martin F Fromm, Harald Hübner, Peter Gmeiner, Olaf Prante\",\"doi\":\"10.1186/s13550-024-01141-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The orexin receptor (OXR) plays a role in drug addiction and is aberrantly expressed in colorectal tumors. Subtype-selective OXR PET ligands suitable for in vivo use have not yet been reported. This work reports the development of <sup>18</sup>F-labeled OXR PET ligand candidates derived from the OXR antagonist suvorexant and the OX1R-selective antagonist JH112.</p><p><strong>Results: </strong>Computational analysis predicted that fluorine substitution (1e) and introduction of the fluorobenzothiazole scaffold (1f) would be suitable for maintaining high OX1R affinity. After multi-step synthesis of 1a-1f, in vitro OXR binding studies confirmed the molecular dynamics calculations and revealed single-digit nanomolar OX1R affinities for 1a-f, ranging from 0.69 to 2.5 nM. The benzothiazole 1f showed high OX1R affinity (K<sub>i</sub> = 0.69 nM), along with 77-fold subtype selectivity over OX2R. Cu-mediated <sup>18</sup>F-fluorination of boroxine precursors allowed for a shortened reaction time of 5 min to provide the non-selective OXR ligand [<sup>18</sup>F]1c and its selective OX1R congener [<sup>18</sup>F]1f in activity yields of 14% and 22%, respectively, within a total synthesis time of 52-76 min. [<sup>18</sup>F]1c and [<sup>18</sup>F]1f were stable in plasma and serum in vitro, with logD<sub>7.4</sub> of 2.28 ([<sup>18</sup>F]1c) and 2.37 ([<sup>18</sup>F]1f), and high plasma protein binding of 66% and 77%, respectively. Dynamic PET imaging in rats showed similar brain uptake of [<sup>18</sup>F]1c (0.17%ID/g) and [<sup>18</sup>F]1f (0.15%ID/g). However, preinjection of suvorexant did not significantly block [<sup>18</sup>F]1c or [<sup>18</sup>F]1f uptake in the rat brain. Pretreatment with cyclosporine A to study the role of P-glycoprotein (P-gp) in limiting brain accumulation moderately increased brain uptake of [<sup>18</sup>F]1c and [<sup>18</sup>F]1f. Accordingly, in vitro experiments demonstrated that the P-gp inhibitor zosuquidar only moderately inhibited polarized, basal to apical transport of 1c (p < 0.05) and had no effect on the transport of 1f, indicating that P-gp does not play a relevant role in brain accumulation of [<sup>18</sup>F]1c and [<sup>18</sup>F]1f in vivo.</p><p><strong>Conclusions: </strong>The in vitro and in vivo results of [<sup>18</sup>F]1c and [<sup>18</sup>F]1f provide a solid basis for further development of suitable OXR PET ligands for brain imaging.</p>\",\"PeriodicalId\":3,\"journal\":{\"name\":\"ACS Applied Electronic Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-09-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11374953/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Electronic Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13550-024-01141-2\",\"RegionNum\":3,\"RegionCategory\":\"材料科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENGINEERING, ELECTRICAL & ELECTRONIC\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13550-024-01141-2","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0

摘要

背景:奥曲肽受体(OXR)在药物成瘾中发挥作用,并在结直肠肿瘤中异常表达。适合体内使用的亚型选择性 OXR PET 配体尚未见报道。本研究报告了从 OXR 拮抗剂 suvorexant 和 OX1R 选择性拮抗剂 JH112 衍生出的 18F 标记 OXR PET 配体候选化合物的开发情况:计算分析预测,氟取代(1e)和引入氟苯并噻唑支架(1f)适合于保持高 OX1R 亲和力。经过多步合成 1a-1f,体外 OXR 结合研究证实了分子动力学计算结果,并发现 1a-f 的 OX1R 亲和力为个位数纳摩尔,从 0.69 到 2.5 nM 不等。苯并噻唑 1f 显示出很高的 OX1R 亲和力(Ki = 0.69 nM),对 OX2R 的亚型选择性高达 77 倍。铜介导的硼氧前体 18F 氟化反应时间缩短了 5 分钟,在总合成时间为 52-76 分钟的情况下,提供了非选择性 OXR 配体 [18F]1c 及其选择性 OX1R 同系物 [18F]1f,活性产率分别为 14% 和 22%。[18F]1c和[18F]1f在体外血浆和血清中稳定,logD7.4分别为2.28([18F]1c)和2.37([18F]1f),血浆蛋白结合率分别为66%和77%。大鼠动态 PET 成像显示,[18F]1c(0.17%ID/g)和[18F]1f(0.15%ID/g)的脑摄取量相似。然而,预先注射舒伐沙坦并不能明显阻止大鼠大脑对[18F]1c或[18F]1f的摄取。为研究 P 糖蛋白(P-gp)在限制脑内蓄积方面的作用,用环孢素 A 预处理可适度增加大脑对 [18F]1c 和 [18F]1f 的摄取。相应地,体外实验表明,P-gp 抑制剂 zosuquidar 只适度抑制体内 1c (p 18F]1c 和 [18F]1f )的极化、基底到顶端转运:[18F]1c和[18F]1f的体外和体内研究结果为进一步开发用于脑成像的合适OXR PET配体奠定了坚实的基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Heteroaryl derivatives of suvorexant as OX1R selective PET ligand candidates: Cu-mediated 18F-fluorination of boroxines, in vitro and initial in vivo evaluation.

Background: The orexin receptor (OXR) plays a role in drug addiction and is aberrantly expressed in colorectal tumors. Subtype-selective OXR PET ligands suitable for in vivo use have not yet been reported. This work reports the development of 18F-labeled OXR PET ligand candidates derived from the OXR antagonist suvorexant and the OX1R-selective antagonist JH112.

Results: Computational analysis predicted that fluorine substitution (1e) and introduction of the fluorobenzothiazole scaffold (1f) would be suitable for maintaining high OX1R affinity. After multi-step synthesis of 1a-1f, in vitro OXR binding studies confirmed the molecular dynamics calculations and revealed single-digit nanomolar OX1R affinities for 1a-f, ranging from 0.69 to 2.5 nM. The benzothiazole 1f showed high OX1R affinity (Ki = 0.69 nM), along with 77-fold subtype selectivity over OX2R. Cu-mediated 18F-fluorination of boroxine precursors allowed for a shortened reaction time of 5 min to provide the non-selective OXR ligand [18F]1c and its selective OX1R congener [18F]1f in activity yields of 14% and 22%, respectively, within a total synthesis time of 52-76 min. [18F]1c and [18F]1f were stable in plasma and serum in vitro, with logD7.4 of 2.28 ([18F]1c) and 2.37 ([18F]1f), and high plasma protein binding of 66% and 77%, respectively. Dynamic PET imaging in rats showed similar brain uptake of [18F]1c (0.17%ID/g) and [18F]1f (0.15%ID/g). However, preinjection of suvorexant did not significantly block [18F]1c or [18F]1f uptake in the rat brain. Pretreatment with cyclosporine A to study the role of P-glycoprotein (P-gp) in limiting brain accumulation moderately increased brain uptake of [18F]1c and [18F]1f. Accordingly, in vitro experiments demonstrated that the P-gp inhibitor zosuquidar only moderately inhibited polarized, basal to apical transport of 1c (p < 0.05) and had no effect on the transport of 1f, indicating that P-gp does not play a relevant role in brain accumulation of [18F]1c and [18F]1f in vivo.

Conclusions: The in vitro and in vivo results of [18F]1c and [18F]1f provide a solid basis for further development of suitable OXR PET ligands for brain imaging.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.20
自引率
4.30%
发文量
567
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信